Percutaneous Closure of Atrial Septal Defects: Immediate and Mid-Term Resultss

Hellenic Journal of Cardiology

Volumn 51, Issue 2, 2010, Pages 104-112

  Dardas, Petros S ^a   Ninios, Vlasis N ^a   Mezilis, Nikolaos E ^a   Tsikaderis, Dimitrios D ^a   Thanopoulos, Vasilis D ^b  

^a St Luke's Hospital   (Greece)

^b Department of Cardiology   (Greece)

Author keywords

Atrial septal defects; Percutaneous closure

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIBIOTIC AGENT; ANTITHROMBOCYTIC AGENT;

ADULT; AMPLATZER CLOSURE DEVICE; ARTICLE; ARTIFICIAL EMBOLISM; BALLOON OCCLUSION; CRYPTOGENIC STROKE; DRESSLER SYNDROME; ENDOCARDITIS; FEMALE; GREECE; HEART ATRIUM FIBRILLATION; HEART ATRIUM SEPTUM DEFECT; HEART RUPTURE; HEART SURGERY; HEART VENTRICLE EXTRASYSTOLE; HUMAN; IMPLANT; IMPLANTATION; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; PATENT FORAMEN OVALE; PERCUTANEOUS CLOSURE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; POSTOPERATIVE THROMBOSIS; RECURRENT DISEASE; ST SEGMENT ELEVATION; STROKE; SUPRAVENTRICULAR PREMATURE BEAT; SURGICAL RISK; SURGICAL TECHNIQUE; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADULT; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; FOLLOW-UP STUDIES; FORAMEN OVALE, PATENT; GREECE; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; INCIDENCE; MALE; POSTOPERATIVE COMPLICATIONS; PROSTHESIS DESIGN; SEPTAL OCCLUDER DEVICE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77950829421     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Holzer R, Hijazi ZM. Interventional approach to congenital heart disease. Curr Opin Cardiol. 2004; 19: 84-90. (Pubitemid 38373118)
2. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP; PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale. Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation 2002; 105: 2625-2631.
3. Bogousslavsky J, Garazi S, Jeanrenaud X, Aebischer N, Van Melle G. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group. Neurology. 1996; 46: 1301-1305.
4. Mas JL, Zuber M. Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm. Am Heart J. 1995; 130: 1083-1088.
5. Nedeltchev K, Arnold M, Wahl A, et al. Outcome of patients with cryptogenic stroke and patent foramen ovale. J Neurol Neurosurg Psychiatry. 2002; 72: 347-350. (Pubitemid 34185204)
6. Hanna JP, Sun JP, Furlan AJ, Stewart WJ, Sila CA, Tan M. Patent foramen ovale and brain infarct. Echocardiographic predictors, recurrence, and prevention. Stroke. 1994; 25: 782-786.
7. Cujec B, Mainra R, Johnson DH. Prevention of recurrent cerebral ischemic events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks. Can J Cardiol. 1999; 15: 57-64. (Pubitemid 29080518)
8. Murat TE. Devices to reduce stroke. J Invasive Cardiol 2004; (Suppl): 54-58.
9. Sievert H, Taaffe M. Patent foramen ovale: The jury is still out. Eur Heart J. 2004; 25: 361-362. (Pubitemid 38391516)
10. Agmon Y, Khandheria BK, Meissner I, et al. Frequency of atrial septal aneurysms in patients with cerebral ischemic events. Circulation. 1999; 99: 1942-1944. (Pubitemid 29183888)
11. Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. 2001; 345: 1740-1746.
12. Srivastava TN, Payment MF. Images in clinical medicine. Paradoxical embolism thrombus in transit through a patent foramen ovale. N Engl J Med. 1997; 337: 681.
13. Windecker S, Wahl A, Nedeltchev K, et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol. 2004; 44: 750-758. (Pubitemid 39099567)
14. Masura J, Gavora P, Formanek A, Hijazi ZM. Transcatheter closure of secundum atrial septal defects using the new selfcentering amplatzer septal occluder: initial human experience. Cathet Cardiovasc Diagn. 1997; 42: 388-393.
15. Berger F, Ewert P, Björnstad PG, et al. Transcatheter closure as standard treatment for most interatrial defects: experience in 200 patients treated with the Amplatzer Septal Occluder. Cardiol Young. 1999; 9: 468-473.
16. Fischer G, Stieh J, Uebing A, Hoffmann U, Morf G, Kramer HH. Experience with transcatheter closure of secundum atrial septal defects using the Amplatzer septal occluder: a single centre study in 236 consecutive patients. Heart. 2003;89:199-204. (Pubitemid 36115108)
17. Webster MW, Chancellor AM, Smith HJ, et al. Patent fora- men ovale in young stroke patients. Lancet. 1988; 2: 11-12.
18. Masura J, Gavora P, Podnar T. Long-term outcome of transcatheter secundum-type atrial septal defect closure using Amplatzer septal occluders. J Am Coll Cardiol. 2005; 45: 505-507. (Pubitemid 40222242)
19. Salehian O, Horlick E, Schwerzmann M, et al. Improvements in cardiac form and function after transcatheter closure of secundum atrial septal defects. J Am Coll Cardiol. 2005; 45: 499-504. (Pubitemid 40222241)
20. Khositseth A, Cabalka AK, Sweeney JP, et al. Transcatheter Amplatzer device closure of atrial septal defect and patent foramen ovale in patients with presumed paradoxical embolism. Mayo Clin Proc. 2004; 79: 35-41. (Pubitemid 38018582)
21. Du ZD, Hijazi ZM, Kleinman CS, Silverman NH, Larntz K. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: results of a multicenter nonrandomized trial. J Am Coll Cardiol. 2002; 39: 1836-1844. (Pubitemid 34595297)
22. Chessa M, Carminati M, Butera G, et al. Early and late complications associated with transcatheter occlusion of secundum atrial septal defect. J Am Coll Cardiol. 2002; 39: 1061-1065. (Pubitemid 34234131)
23. Preventza O, Sampath-Kumar S, Wasnick J, Gold JP. Late cardiac perforation following transcatheter atrial septal defect closure. Ann Thorac Surg. 2004; 77: 1435-1437. (Pubitemid 38452397)
24. Chun DS, Turrentine MW, Moustapha A, Hoyer MH. Development of aorta-to-right atrial fistula following closure of secundum atrial septal defect using the Amplatzer septal occluder. Catheter Cardiovasc Interv. 2003; 58: 246-251. (Pubitemid 36159572)
25. Hill SL, Berul CI, Patel HT, et al. Early ECG abnormalities associated with transcatheter closure of atrial septal defects using the Amplatzer septal occluder. J Interv Card Electrophysiol. 2000; 4: 469-474.
26. Levi DS, Moore JW. Embolization and retrieval of the Am- platzer septal occluder. Catheter Cardiovasc Interv. 2004; 61: 543-547.
27. Verma PK, Thingnam SKS, Sharma A, Taneja JS, Varma JS, Grover A. Delayed embolization of Amplatzer septal occluder device: an unknown entity-a case report. Angiology. 2003; 54: 115-118. (Pubitemid 36222550)
28. Krumsdorf U, Ostermayer S, Billinger K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol. 2004; 43: 302-309. (Pubitemid 38201160)
29. Anzai H, Child J, Natterson B, et al. Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices. Am J Cardiol. 2004; 93: 426-431. (Pubitemid 38221349)
30. Amin Z, Hijazi ZM, Bass JL, Cheatham JP, Hellenbrand WE, Kleinman CS. Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc Interv. 2004; 63: 496-502. (Pubitemid 39578516)
31. Divekar A, Gaamangwe T, Shaikh N, Raabe M, Ducas J. Cardiac perforation after device closure of atrial septal defects with the Amplatzer septal occluder. J Am Coll Cardiol. 2005; 45: 1213-1218. (Pubitemid 40523139)
32. Bullock AM, Menahem S, Wilkinson JL. Infective endocarditis on an occluder closing an atrial septal defect. Cardiol Young. 1999; 9: 65-67.
33. Cao QL, Du ZD, Joseph A, et al. Immediate and six-month results of the profile of the Amplatzer septal occluder as assessed by transesophageal echocardiography. Am J Cardiol. 2001; 88: 754-759.
34. Hara H, Virmani R, Ladich E, et al. Patent foramen ovale: current pathology, pathophysiology, and clinical status. J Am Coll Cardiol. 2005; 46: 1768-1776. (Pubitemid 41531637)
35. Wu LA, Malouf JF, Dearani JA, et al. Patent foramen ovale in cryptogenic stroke: current understanding and management options. Arch Intern Med. 2004; 164: 950-956. (Pubitemid 38581513)
36. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984; 59: 17-20.
37. Fisher DC, Fisher EA, Budd JH, Rosen SE, Goldman ME. The incidence of patent foramen ovale in 1,000 consecutive patients. A contrast transesophageal echocardiography study. Chest. 1995; 107: 1504-1509.
38. Steiner MM, Di Tullio MR, Rundek T, et al. Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke. Stroke. 1998; 29: 944-948. (Pubitemid 28228154)
39. Falk V, Walther T, Krankenberg H, Mohr FW. Trapped thrombus in a patent foramen ovale. Thorac Cardiovasc Surg. 1997; 45: 90-92. (Pubitemid 27224021)
40. Kessel-Schaefer A, Lefkovits M, Zellweger MJ, et al. Migrating thrombus trapped in a patent foramen ovale. Circulation. 2001; 103: 1928. (Pubitemid 32328409)
41. Homma S, Di Tullio MR, Sacco RL, Mihalatos D, Li Mandri G, Mohr JP. Characteristics of patent foramen ovale associated with cryptogenic stroke. A biplane transesophageal echocardiographic study. Stroke. 1994; 25: 582-586.
42. Hausmann D, Mügge A, Daniel WG. Identification of patent foramen ovale permitting paradoxic embolism. J Am Coll Cardiol. 1995; 26: 1030-1038.
43. Stone DA, Godard J, Corretti MC, et al. Patent foramen ovale: association between the degree of shunt by contrast transesophageal echocardiography and the risk of future ischemic neurologic events. Am Heart J. 1996; 131: 158-161. (Pubitemid 26021379)
44. Schuchlenz HW, Weihs W, Horner S, Quehenberger F. The association between the diameter of a patent foramen ovale and the risk of embolic cerebrovascular events. Am J Med. 2000; 109: 456-462.
45. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001; 345: 1444-1451.
46. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med. 2003; 139: 753-760. (Pubitemid 38129075)
47. Windecker S, Wahl A, Chatterjee T, et al. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation. 2000; 101: 893-898. (Pubitemid 30117885)
48. Braun MU, Fassbender D, Schoen SP, et al. Transcatheter closure of patent foramen ovale in patients with cerebral ischemia. J Am Coll Cardiol. 2002; 39: 2019-2025. (Pubitemid 34628285)
49. Martín F, Śnchez PL, Doherty E, et al. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation. 2002; 106: 1121-1126.
50. Du Z-D, Cao Q-L, Joseph A, et al. Transcatheter closure of patent foramen ovale in patients with paradoxical embolism: intermediate-term risk of recurrent neurological events. Catheter Cardiovasc Interv. 2002; 55: 189-194. (Pubitemid 34127378)
51. Hong TE, Thaler D, Brorson J, Heitschmidt M, Hijazi ZM. Transcatheter closure of patent foramen ovale associated with paradoxical embolism using the amplatzer PFO occluder: initial and intermediate-term results of the U.S. multicenter clinical trial. Catheter Cardiovasc Interv. 2003; 60: 524-528. (Pubitemid 37466763)
52. Braun M, Gliech V, Boscheri A, et al. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems. Eur Heart J. 2004; 25: 424-430.
53. Bruch L, Parsi A, Grad MO, et al. Transcatheter closure of interatrial communications for secondary prevention of paradoxical embolism: single-center experience. Circulation. 2002; 105: 2845-2848. (Pubitemid 34666096)
54. Thanopoulos BVD, Dardas PD, Karanasios E, Mezilis N. Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke. Catheter Cardiovasc Interv. 2006; 68: 741-746. (Pubitemid 44721098)
55. Meier B. Closure of patent foramen ovale: technique, pitfalls, complications, and follow up. Heart 2005; 91: 444-448. (Pubitemid 40432763)
56. Ganado CC, Felice H, Aquilina O, et al. Atrial fibrillation following transcatheter closure of patent foramen ovale. Hellenic J Cardiol. 2008; 49: 59. (Pubitemid 351499664)
57. Balbi M, Casalino L, Gnecco G, et al. Percutaneous closure of patent foramen ovale in patients with presumed paradoxical embolism: periprocedural results and midterm risk of recurrent neurologic events. Am Heart J. 2008; 156: 356-360.
58. Egred M, Andron M, Albouaini K, Alahmar A, Grainger R, Morrison WL. Percutaneous closure of patent foramen ovale and atrial septal defect: procedure outcome and mediumterm follow-up. J Interv Cardiol. 2007; 20: 395-401. (Pubitemid 47429143)